全球智库信息集成服务系统(G2TT): What's the \"Interest\" in FDA Drug Advisory Committee Conflicts of Interest?

G2TT

来源类型	Working Paper
规范类型	报告
DOI	10.3386/w14932
来源ID	Working Paper 14932
	What's the \"Interest\" in FDA Drug Advisory Committee Conflicts of Interest?
	Joseph Golec; John Vernon
发表日期	2009-04-30
出版年	2009
语种	英语
摘要	Food and Drug Administration (FDA) drug advisory committee members sometimes have financial interests tied to drug companies. Congress and the public have become concerned that these financial interests lead to conflicts of interest. They conclude that the conflicts bias committee recommendations, and lead to unsafe or ineffective drugs being approved for public consumption, or, conversely, delays in approval of safe and effective drugs. Our paper provides empirical evidence, based on an event study methodology, that advisory committee meetings lead to weak or statistically insignificant effects on stock prices and hence equity values of regulated companies assumed to be affected by the particular matters coming before committee meetings.
主题	Financial Economics ; Financial Markets ; Corporate Finance ; Health, Education, and Welfare ; Health ; Education
URL	https://www.nber.org/papers/w14932
来源智库	National Bureau of Economic Research (United States)
引用统计
资源类型	智库出版物
条目标识符	http://119.78.100.153/handle/2XGU8XDN/572608
推荐引用方式 GB/T 7714	Joseph Golec,John Vernon. What's the \"Interest\" in FDA Drug Advisory Committee Conflicts of Interest?. 2009.

条目包含的文件
文件名称/大小	资源类型	版本类型	开放类型	使用许可
w14932.pdf（121KB）	智库出版物		限制开放	CC BY-NC-SA	浏览